Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
Shares of the international gene therapy developer uniQure (NASDAQ: QURE) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's...
uniQure Announces FDA Agreement on Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
The FDA supports uniQure's AMT-130 for Huntington's disease under an Accelerated Approval pathway using existing study data.Quiver AI SummaryuniQure N.V. announced that the U.S. Food and Drug Administration...
uniQure’s AMT-130 previously received a regenerative medicine advanced therapy designation from the FDA in May.
uniQure N.V. Initiates Phase I/IIa Clinical Trial for AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
uniQure initiates GenTLE trial, dosing first patient with AMT-260 for refractory mesial temporal lobe epilepsy treatment.Quiver AI SummaryuniQure N.V. announced the dosing of the first patient in its GenTLE...